SEALIVE:肝移植受体肝切除术中血管封闭装置应用随机对照试验方案
SEALIVE 是一项单中心、前瞻性、随机、对照、平行、三臂、确证性、开放性试验,比较 LigaSure™ 和 HARMONIC ACE®+7 与标准手术技术(钛夹和传统打结结扎)在肝移植受体肝切除术中的效果。主要终点为术中总失血量,每组按方案分析 23 例,意向性分析纳入 69 例患者,随访 90 天。
要点
- 比较两种血管封闭装置与标准技术在受体肝切除术中的失血量差异。
- 主要终点为术中总失血量,每组需按方案分析 23 例。
- 意向性分析计划纳入 69 例患者,安全性随访 90 天。
核心结论
- 该试验旨在检测两种创新血管封闭与分离技术相比标准技术能否在肝移植受体肝切除术中显著减少术中失血量。
研究设计与样本
- 单中心、前瞻性、随机、对照、平行、三臂、确证性、开放性试验,比较 LigaSure™、HARMONIC ACE®+7 与标准手术技术(钛夹和传统打结结扎)。
- 在 80% 把握度和两个实验组 alpha 均为 0.025 的条件下,每组按方案分析 23 例受试者,意向性分析纳入 69 例患者。
- 每例患者安全性随访 90 天,所有临床结局在术后前 10 天内测量。
主要发现
- 原文未报告试验结果。
关键数值与推荐
- 主要终点为术中总失血量。
- 次要终点包括肝切除术中失血量、肝切除术和整个手术的持续时间以及手术输血需求。
- 术中失血量记录需考虑手术中所有冲洗液、腹水以及称重使用过的纱布。
临床怎么用
- 该试验结果预期可改善肝移植术后患者结局和安全性,并提高该手术的普遍安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The surgical technique used in liver transplantation has undergone constant evolution in an effort to develop a safe, highly standardized procedure. Despite this, the initial step of recipient hepatectomy has not been the focus of clinical research thus far. Due to advanced coagulopathy in liver transplant recipients, this part of the operation still carries the risk of severe hemorrhage. This trial is designed to compare an electrothermal bipolar vessel sealing device (LigaSure™) and an ultrasound dissector (HARMONIC ACE®+7) with standard surgical techniques during the recipients' hepatectomy in liver transplantation. METHODS/DESIGN: In a single-center, prospective, randomized, controlled, parallel, three-armed, confirmatory, open trial, LigaSure™ and HARMONIC ACE®+7 will be compared with standard surgical techniques that use titanium clips and conventional knot-tying ligations during recipient hepatectomy in liver transplantation. Intraoperative total blood loss is the primary endpoint of the trial. Secondary endpoints include blood loss during hepatectomy, the duration of both the hepatectomy and the entire surgical procedure, and blood transfusion requirements of the procedure. To generate reliable data, intraoperative blood loss will be recorded with respect to all rinse fluids during surgery, ascites, and by weighing used swabs. At 80% power and an alpha of 0.025 for both of the experimental groups, 23 subjects will be analyzed per protocol in each study arm in order to detect clinically relevant reduction of intraoperative blood loss. The intention-to-treat analysis will include 69 patients. The follow-up period for each patient will be 90 days for safety reasons, whereas all clinical outcomes will be measured within the first 10 postoperative days. DISCUSSION: To our knowledge, this is the first prospective, randomized trial comparing two innovative technical methods of vessel sealing and dissection with standard techniques for recipient hepatectomy. This will be done to detect relevant reduction of intraoperative blood loss during liver transplant. The results of the trial are expected to improve patient outcome and safety after liver transplant and to increase the general safety of this procedure. TRIAL REGISTRATION: ClinicalTrials.gov, NCT 03323242 . Registered on October 26, 2017.
引用
- Houben P, Khajeh E, Hinz U, et al. SEALIVE: the use of technical vessel-sealing devices for recipient hepatectomy in liver transplantation: study protocol for a randomized controlled trial. Trials. 2018. PMID: 30012178. doi:10.1186/s13063-018-2778-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。